Therion Biologics Corporation Report issue

For profit Phase 2 Phase 3
Founded: Cambridge MA United States (1991)
Status: Defunct (2014)

Organization Overview

First Clinical Trial
2003
NCT00078585
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

falimarev (1 trial)

Drugs in Phase 2 Trials (2)

metronidazole (flagyl) (1 trial)

rilimogene gamvacirepvec (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3